CD19 Antibody (BCE19): sc-69736
- CD19 Antibody (BCE19) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against A20/CD19 transfectant of human origin
- recommended for detection of CD19 on normal and neoplastic B lymphocytes of human origin by IP, IF and FCM
- available conjugated to FITC for IF, IHC(P) and FCM
- See CD19 (B-1): sc-390244 for CD19 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for CD19 Antibody (BCE19). These reagents are now offered in bundles with CD19 Antibody (BCE19) (see ordering information below).
QUICK LINKS
SEE ALSO...
CD19 Antibody (BCE19) is a mouse monoclonal IgG1 antibody that detects CD19 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD19 is a crucial transmembrane glycoprotein that plays a significant role in B-cell development and activation, as anti-CD19 antibody (BCE19) selectively recognizes proteins expressed on the surface of B-lymphocytes. CD19 contains two extracellular immunoglobulin-like domains, which are essential for activating intracellular signaling pathways, including the Ras and phosphatidylinositol 3-kinase pathways. CD19 activation leads to the cross-linking of immunoglobulin chains on the membrane, facilitating the association with Src family protein tyrosine kinases, which are vital for downstream signaling events. CD19 is continuously expressed throughout the various stages of B-cell development, including the terminal differentiation into plasma cells, making CD19 (BCE19) monoclonal antibody a reliable marker for identifying B-cells. CD19 forms functional complexes with other B-lymphocyte surface proteins, such as integrin β1, CD21, and CD81, which are integral to regulating B-cell maturation and function. CD19 (BCE19) antibody serves as an invaluable tool for researchers studying B-cell biology and related immunological processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD19 Antibody (BCE19) References:
- Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. | Katz, BZ. and Herishanu, Y. 2014. Leuk Lymphoma. 55: 999-1006. PMID: 23885836
- Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. | Raufi, A., et al. 2013. Cancer Manag Res. 5: 225-33. PMID: 24023523
- CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia. | Weiland, J., et al. 2015. Pediatr Blood Cancer. 62: 1144-8. PMID: 25755168
- The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. | Lykken, JM. and Tedder, TF. 2015. Cancer J. 21: 351-6. PMID: 26222089
- Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. | Nie, Y., et al. 2020. Biomark Res. 8: 18. PMID: 32514351
- Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers. | Blanco, B., et al. 2022. Cancer Immunol Res. 10: 498-511. PMID: 35362043
- Anti-CD19 CAR T-cell consolidation therapy combined with CD19+ feeding T cells and TKI for Ph+ acute lymphoblastic leukemia. | Chen, LY., et al. 2023. Blood Adv. 7: 4913-4925. PMID: 36897251
- Inherited CD19 Deficiency Does Not Impair Plasma Cell Formation or Response to CXCL12. | Walker, K., et al. 2023. J Clin Immunol. 43: 1543-1556. PMID: 37246174
- Elevated circulating CD19+CD24hiCD38hi B cells display pro-inflammatory phenotype in idiopathic membranous nephropathy. | Deng, B., et al. 2023. Immunol Lett. 261: 58-65. PMID: 37553031
- CD19 regulates B lymphocyte responses to transmembrane signals. | Fujimoto, M., et al. 1998. Semin Immunol. 10: 267-77. PMID: 9695183
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD19 Antibody (BCE19) | sc-69736 | 200 µg/ml | $322.00 | |||
CD19 Antibody (BCE19): m-IgG Fc BP-HRP Bundle | sc-539235 | 200 µg Ab; 10 µg BP | $361.00 | |||
CD19 Antibody (BCE19): m-IgG1 BP-HRP Bundle | sc-541343 | 200 µg Ab; 20 µg BP | $361.00 | |||
CD19 Antibody (BCE19) FITC | sc-69736 FITC | 200 µg/ml | $336.00 |